Fundacion Inciensa

Fundacion Inciensa is a non-profit organization and foundation based in Cartago Province, Costa Rica, registered in SAM.gov since 2004 with a current registration valid through September 11, 2025. The organization specializes in providing epidemiological, clinical, and laboratory research services to the U.S. federal government, with a particular focus on infectious disease research, vaccine studies, and public health investigations. While specific details about the organization's broader mission are not provided, its federal contract history demonstrates a strong commitment to international medical research collaboration, primarily with the National Cancer Institute (NCI).

Through its federal contract awards, Fundacion Inciensa has consistently delivered specialized research services focused on human papillomavirus (HPV) vaccine studies, COVID-19 transmission research, and related epidemiological investigations. The organization has received multiple prime contract awards from the National Cancer Institute, totaling approximately $36 million across several contracts ranging from $700,447 to $20,168,469. These contracts involve conducting clinical trials, collecting and analyzing data, performing laboratory testing, and researching disease transmission and vaccine efficacy. All of the organization's federal contract awards have been firm fixed-price delivery orders with no specific set-aside designations, and they have consistently supported the NCI's research objectives in epidemiology and infectious disease prevention.

Fundacion Inciensa holds a single-award Indefinite Delivery Contract (IDC) with the National Cancer Institute, valued at $49 million and running through August 2034. This comprehensive IDC enables the organization to provide ongoing epidemiological, clinical, and laboratory research services related to cancer, vaccines, and infectious diseases. The contract specifically covers conducting human papillomavirus vaccine trials, evaluating single-dose vaccine protection, following up with study participants, and testing biospecimens. The initial $2,808 delivery order under this IDC will support "Epidemiology and Prevention of Infections and Related Diseases" efforts through September 2024, with potential for additional task orders throughout the contract's duration. This IDC represents a significant long-term research partnership between Fundacion Inciensa and the National Institutes of Health.